Lie Lin
Haikou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.
Journal: Journal for immunotherapy of cancer
Published: October 03, 2024
A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia.
Journal: American journal of hematology
Published: January 28, 2024
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Journal: The Lancet. Oncology
Published: September 28, 2023
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors.
Journal: Oncology and therapy
Published: September 01, 2023
Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey.
Journal: Leukemia & lymphoma
Published: June 07, 2023
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Journal: Cancer medicine
Published: September 02, 2021
microRNA-22 can regulate expression of the long non-coding RNA MEG3 in acute myeloid leukemia.
Journal: Oncotarget
Published: March 22, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026